Literature DB >> 17448140

Overexpression of cyclooxygenase-2 correlates with cytoplasmic HuR expression in salivary mucoepidermoid carcinoma but not in pleomorphic adenoma.

Nam-Pyo Cho1, Hye-Suk Han, Yunjo Soh, Hyun-Jin Son.   

Abstract

BACKGROUND: The overexpression of cyclooxygenase (COX)-2 in several human carcinomas suggests that COX-2 is related to carcinogenesis. Although COX-2 expression has been shown to be up-regulated in carcinomas of the salivary gland, its mechanisms are not completely understood. HuR is an mRNA-binding protein that controls the stability of certain transcripts including COX-2.
METHODS: The expression of COX-2 and HuR was determined by immunohistochemistry in 28 cases of salivary pleomorphic adenoma and 18 cases of salivary mucoepidermoid carcinoma.
RESULTS: 28.6% and 72.2% of the pleomorphic adenomas and mucoepidermoid carcinomas showed high COX-2 expression respectively. 35.7% of pleomorphic adenomas and 72.2% of mucoepidermoid carcinomas were tested positive for HuR in the cytoplasm of tumor cells. There was a correlation between a high COX-2 immunoreactivity and cytoplasmic HuR expression in mucoepidermoid carcinomas but not in pleomorphic adenomas.
CONCLUSION: This study suggests that cytoplasmic HuR is correlated with COX-2 expression in salivary mucoepidermoid carcinomas. In addition, the immunoreactivity of COX-2 and cytoplasmic HuR might be used to evaluate the nature of a borderline malignancy in the salivary glands.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448140     DOI: 10.1111/j.1600-0714.2007.00526.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  18 in total

Review 1.  Posttranscriptional regulation of cancer traits by HuR.

Authors:  Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2010-05-06       Impact factor: 9.957

Review 2.  Control of cytokine mRNA expression by RNA-binding proteins and microRNAs.

Authors:  V Palanisamy; A Jakymiw; E A Van Tubergen; N J D'Silva; K L Kirkwood
Journal:  J Dent Res       Date:  2012-02-01       Impact factor: 6.116

3.  The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells.

Authors:  Michael R Epis; Andrew Barker; Keith M Giles; Dianne J Beveridge; Peter J Leedman
Journal:  J Biol Chem       Date:  2011-10-04       Impact factor: 5.157

Review 4.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

5.  Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma.

Authors:  Cong Zhang; Guoliang Xue; Jingwang Bi; Ming Geng; Huili Chu; Yaping Guan; Jun Wang; Baocheng Wang
Journal:  Tumour Biol       Date:  2013-07-20

6.  Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors.

Authors:  Jefferson da Rocha Tenório; Leorik Pereira da Silva; Marília Gabriela de Aguiar Xavier; Thalita Santana; George João Ferreira do Nascimento; Ana Paula Veras Sobral
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-07-12       Impact factor: 2.503

7.  Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas.

Authors:  Takahiro Sakuma; Takao Nakagawa; Kazunori Ido; Hiroaki Takeuchi; Kazufumi Sato; Toshihiko Kubota
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

8.  AUF1 and HuR proteins stabilize interleukin-8 mRNA in human saliva.

Authors:  V Palanisamy; N J Park; J Wang; D T Wong
Journal:  J Dent Res       Date:  2008-08       Impact factor: 6.116

Review 9.  HuR function in disease.

Authors:  Subramanya Srikantan; Myriam Gorospe
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

10.  HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells.

Authors:  H Hasegawa; W Kakuguchi; T Kuroshima; T Kitamura; S Tanaka; Y Kitagawa; Y Totsuka; M Shindoh; F Higashino
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.